RxDoctor Payments Data

Toni Meeks, MD

Internal Medicine · Fayetteville, NCNPI 1780617514

Payments from drug & device makers

$3,894in general payments, 2019–2025

Across 237 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$628
  • Novo Nordisk$578
  • Boehringer Ingelheim$386
  • Amgen$283
  • GSK$275
  • Pfizer$229
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,81998%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,894 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$229,883
Medicare patients
235
Services billed
4,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide68$103,861
MounjaroTirzepatide82$88,948
Repatha SureclickEvolocumab94$69,688
JardianceEmpagliflozin59$69,026
ArexvyRsvpref3 Antigen/As01e/Pf158$48,626
EliquisApixaban55$41,968
OzempicSemaglutide29$41,132
ShingrixVaricella-Zoster Ge/As01b/Pf82$18,393
TrulicityDulaglutide12$16,591
MyrbetriqMirabegron17$14,719
Praluent PenAlirocumab11$13,965
Levothyroxine Sodium379$6,650
Repatha SyringeEvolocumab12$6,603
Pitavastatin Calcium21$6,050
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf76$5,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$578$144,99397 claims
Lilly USA, LLCMounjaro, Trulicity$628$105,54094 claims
Boehringer IngelheimJardiance$386$69,02659 claims
GSKArexvy, Shingrix$275$67,018240 claims
PfizerEliquis$229$41,96855 claims
Astellas Pharma US IncMyrbetriq$97$14,71917 claims
AbbVieSynthroid$173$2,50720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →